Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
FibroGen Inc
FGEN | US
0.37
USD-0.02
-4.34%
FGEN | US
About FibroGen Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
0.37
Open
0.40
High
0.40
Low
0.35
FibroGen Inc. a biopharmaceutical company discovers develops and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis pancreatic cancer and Duchenne muscular dystrophy; and Roxadustat an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China Europe Japan and other countries as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen Inc. was incorporated in 1993 and is headquartered in San Francisco California.
View LessFGEN | US
Risk
75.3
Sharpe
-0.31
Luna's Score
48/100
Recommendation
Hold
Luna says (FGEN | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
Weakness based on declining price with high volume
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
73.2%1 month
75.3%3 months
136.1%6 months
118.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
61.35
Price to book
53.83
Debt to equity
-0.70
Debt to assets
0.56
Ent. to EBITDA
-0.17
Ent. to rev.
0.26
PEG
-
Other Fundamentals
EBITDA
-165.84M
MarketCap
37.60M
MarketCap(USD)
37.60M
Div. yield
-
Op. margin
-21.56
Erngs. growth
53.60
Rev. growth
14.30
Ret. on equity
-1.02K
Short ratio
5.01
Short perc.
5.33
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.10
Range1M
0.13
Range3M
1.23
Volumes: Market Activity
Rel. volume
1.11
Price X volume
438.69K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.17 | - | Cheaper |
| Ent. to Revenue | 0.26 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 53.83 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 136.13 | - | Riskier |
| Debt to Equity | -0.70 | -1.23 | Expensive |
| Debt to Assets | 0.56 | 0.25 | Expensive |
| Market Cap | 37.60M | - | Emerging |
